A framework and road map for rapid start-up and completion of a COVID-19 vaccine trial: A single clinical trial site experience

The COVID-19 global pandemic required the rapid development of vaccines with a quick start up of phase 1–3 studies with large enrollment targets. The University of California San Diego was identified as a site for the phase 3 trial of the mRNA-1273-SARS-CoV-2 vaccine. There were many challenges with...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical and translational science Vol. 6; no. 1; p. e21
Main Authors Rojas, Carlos, Spector, Stephen A., Cale, Bernadette, Loughran, Megan, Lazaro, Leander, Mah, Eric, Firestein, Gary S., Gold, Kathryn A., Wallace, Mark
Format Journal Article
LanguageEnglish
Published England Cambridge University Press 2022
Subjects
Online AccessGet full text
ISSN2059-8661
2059-8661
DOI10.1017/cts.2022.3

Cover

More Information
Summary:The COVID-19 global pandemic required the rapid development of vaccines with a quick start up of phase 1–3 studies with large enrollment targets. The University of California San Diego was identified as a site for the phase 3 trial of the mRNA-1273-SARS-CoV-2 vaccine. There were many challenges with scaling up a large-scale clinical trial in such a short time. This report describes the processes and procedures that were implemented to successfully complete the enrollment target in under 10 weeks. This required the team to identify existing tools that could rapidly be accessed to develop a database, scheduling system, effective communication, document management, staff time tracking/efficiency, subject scheduling/tracking, project management, and accrual/study performance. The outcome of these efforts resulted in rapid enrollment and study completion in a short time. The lessons learned from this experience can be used by other clinical trial sites faced with similar challenges.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Case Study-2
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2059-8661
2059-8661
DOI:10.1017/cts.2022.3